Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s Idrebormilast?

Idrebormilast is a small molecule commercialized by Pfizer, with a leading Phase II program in Rosacea.

Jul 2, 2024 - 04:00
Idrebormilast is a small molecule commercialized by Pfizer, with a leading Phase II program in Rosacea.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Osive...

Next Article

The Gut-Hormone Connection: How Probiotics Support Women’s Hormones

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year

STAT+: Nimbus Therapeutics raises $210 million in one o...

Sep 6, 2023

Want a biotech buyout? Target cancer

Want a biotech buyout? Target cancer

Oct 10, 2023

SK bioscience’s typhoid vaccine receives WHO prequalification

SK bioscience’s typhoid vaccine receives WHO prequalifi...

Feb 26, 2024